Abstract
The treatment landscape of adjuvant melanoma is evolving with the introduction of targeted therapy (i.e. dabrafenib plus trametinib) and immune checkpoint inhibitors such as pembrolizumab and nivolumab. The objective was to compare efficacy of dabrafenib plus trametinib against other approved adjuvant therapies for melanoma via network meta-analysis (NMA) based on an SLR update.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
